Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma

D. Cantero, H. Friess, J. Deflorin, A. Zimmermann, M. A. Bründler, E. Riesle, Murray Korc, M. W. Büchler

Research output: Contribution to journalArticle

166 Citations (Scopus)

Abstract

Urokinase plasminogen activator (uPA) is a serine proteinase that has been suggested to play an important role in cancer invasion and metastasis. It binds to a specific membrane receptor denominated uPA receptor (uPAR). uPA activates plasminogen to form plasmin, which participates in tissue degradation and proteolysis. Binding of uPA to its receptor accelerates UPA's own activation from pro-uPA, enhancing the activity of the uPA/uPAR cascade. Using immunohistochemistry and Northern blot analysis, we analysed the role of uPA and uPAR in 30 human pancreatic cancers. Immunohistochemical analysis demonstrated moderate to strong immunostaining of both factors in most pancreatic cancers. Cancer lesions with signs of invasion exhibited the strongest immunohistochemical signals for both factors. In addition, in desmoplastic areas adjacent to the cancer cells, moderate uPA and uPAR immunoreactivity was detectable. Northern blot analysis revealed a sixfold and a fourfold increase in uPA and uPAR mRNA levels in pancreatic cancer, respectively, in comparison with normal controls (P <0.01). Correlation of the Northern blot data with the clinical parameters of the patients indicated that patients with concomitant overexpression of uPA and uPAR had a shorter post-operative survival (median 9 months; mean ± s.d. 10.2 ± 3.6 months) than patients in whom only one or none of these factors were overexpressed (median 18 months; mean ± s.d, 20.3 ± 8.7 months) (P <0.002). Our data suggest that uPA and uPAR may serve as prognostic markers in human pancreatic cancer and that the marked overexpression of both factors may create an environment that enables pancreatic cancer cells to invade surrounding tissues.

Original languageEnglish (US)
Pages (from-to)388-395
Number of pages8
JournalBritish Journal of Cancer
Volume75
Issue number3
StatePublished - 1997
Externally publishedYes

Fingerprint

Urokinase Plasminogen Activator Receptors
Pancreatic Neoplasms
Plasminogen Activators
Urokinase-Type Plasminogen Activator
Northern Blotting
saruplase
Neoplasms
Plasminogen
Fibrinolysin
Serine Proteases
Pancreatic Carcinoma
Proteolysis
Immunohistochemistry
Neoplasm Metastasis
Messenger RNA
Membranes
Survival

Keywords

  • Immunohistochemistry
  • Northern blot analysis
  • Pancreatic cancer
  • Urokinase plasminogen activator (uPA)
  • Urokinase plasminogen activator receptor (uPAR)

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cantero, D., Friess, H., Deflorin, J., Zimmermann, A., Bründler, M. A., Riesle, E., ... Büchler, M. W. (1997). Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. British Journal of Cancer, 75(3), 388-395.

Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. / Cantero, D.; Friess, H.; Deflorin, J.; Zimmermann, A.; Bründler, M. A.; Riesle, E.; Korc, Murray; Büchler, M. W.

In: British Journal of Cancer, Vol. 75, No. 3, 1997, p. 388-395.

Research output: Contribution to journalArticle

Cantero, D, Friess, H, Deflorin, J, Zimmermann, A, Bründler, MA, Riesle, E, Korc, M & Büchler, MW 1997, 'Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma', British Journal of Cancer, vol. 75, no. 3, pp. 388-395.
Cantero D, Friess H, Deflorin J, Zimmermann A, Bründler MA, Riesle E et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. British Journal of Cancer. 1997;75(3):388-395.
Cantero, D. ; Friess, H. ; Deflorin, J. ; Zimmermann, A. ; Bründler, M. A. ; Riesle, E. ; Korc, Murray ; Büchler, M. W. / Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. In: British Journal of Cancer. 1997 ; Vol. 75, No. 3. pp. 388-395.
@article{6e547bd5b8d44bffb785e6776e758da0,
title = "Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma",
abstract = "Urokinase plasminogen activator (uPA) is a serine proteinase that has been suggested to play an important role in cancer invasion and metastasis. It binds to a specific membrane receptor denominated uPA receptor (uPAR). uPA activates plasminogen to form plasmin, which participates in tissue degradation and proteolysis. Binding of uPA to its receptor accelerates UPA's own activation from pro-uPA, enhancing the activity of the uPA/uPAR cascade. Using immunohistochemistry and Northern blot analysis, we analysed the role of uPA and uPAR in 30 human pancreatic cancers. Immunohistochemical analysis demonstrated moderate to strong immunostaining of both factors in most pancreatic cancers. Cancer lesions with signs of invasion exhibited the strongest immunohistochemical signals for both factors. In addition, in desmoplastic areas adjacent to the cancer cells, moderate uPA and uPAR immunoreactivity was detectable. Northern blot analysis revealed a sixfold and a fourfold increase in uPA and uPAR mRNA levels in pancreatic cancer, respectively, in comparison with normal controls (P <0.01). Correlation of the Northern blot data with the clinical parameters of the patients indicated that patients with concomitant overexpression of uPA and uPAR had a shorter post-operative survival (median 9 months; mean ± s.d. 10.2 ± 3.6 months) than patients in whom only one or none of these factors were overexpressed (median 18 months; mean ± s.d, 20.3 ± 8.7 months) (P <0.002). Our data suggest that uPA and uPAR may serve as prognostic markers in human pancreatic cancer and that the marked overexpression of both factors may create an environment that enables pancreatic cancer cells to invade surrounding tissues.",
keywords = "Immunohistochemistry, Northern blot analysis, Pancreatic cancer, Urokinase plasminogen activator (uPA), Urokinase plasminogen activator receptor (uPAR)",
author = "D. Cantero and H. Friess and J. Deflorin and A. Zimmermann and Br{\"u}ndler, {M. A.} and E. Riesle and Murray Korc and B{\"u}chler, {M. W.}",
year = "1997",
language = "English (US)",
volume = "75",
pages = "388--395",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma

AU - Cantero, D.

AU - Friess, H.

AU - Deflorin, J.

AU - Zimmermann, A.

AU - Bründler, M. A.

AU - Riesle, E.

AU - Korc, Murray

AU - Büchler, M. W.

PY - 1997

Y1 - 1997

N2 - Urokinase plasminogen activator (uPA) is a serine proteinase that has been suggested to play an important role in cancer invasion and metastasis. It binds to a specific membrane receptor denominated uPA receptor (uPAR). uPA activates plasminogen to form plasmin, which participates in tissue degradation and proteolysis. Binding of uPA to its receptor accelerates UPA's own activation from pro-uPA, enhancing the activity of the uPA/uPAR cascade. Using immunohistochemistry and Northern blot analysis, we analysed the role of uPA and uPAR in 30 human pancreatic cancers. Immunohistochemical analysis demonstrated moderate to strong immunostaining of both factors in most pancreatic cancers. Cancer lesions with signs of invasion exhibited the strongest immunohistochemical signals for both factors. In addition, in desmoplastic areas adjacent to the cancer cells, moderate uPA and uPAR immunoreactivity was detectable. Northern blot analysis revealed a sixfold and a fourfold increase in uPA and uPAR mRNA levels in pancreatic cancer, respectively, in comparison with normal controls (P <0.01). Correlation of the Northern blot data with the clinical parameters of the patients indicated that patients with concomitant overexpression of uPA and uPAR had a shorter post-operative survival (median 9 months; mean ± s.d. 10.2 ± 3.6 months) than patients in whom only one or none of these factors were overexpressed (median 18 months; mean ± s.d, 20.3 ± 8.7 months) (P <0.002). Our data suggest that uPA and uPAR may serve as prognostic markers in human pancreatic cancer and that the marked overexpression of both factors may create an environment that enables pancreatic cancer cells to invade surrounding tissues.

AB - Urokinase plasminogen activator (uPA) is a serine proteinase that has been suggested to play an important role in cancer invasion and metastasis. It binds to a specific membrane receptor denominated uPA receptor (uPAR). uPA activates plasminogen to form plasmin, which participates in tissue degradation and proteolysis. Binding of uPA to its receptor accelerates UPA's own activation from pro-uPA, enhancing the activity of the uPA/uPAR cascade. Using immunohistochemistry and Northern blot analysis, we analysed the role of uPA and uPAR in 30 human pancreatic cancers. Immunohistochemical analysis demonstrated moderate to strong immunostaining of both factors in most pancreatic cancers. Cancer lesions with signs of invasion exhibited the strongest immunohistochemical signals for both factors. In addition, in desmoplastic areas adjacent to the cancer cells, moderate uPA and uPAR immunoreactivity was detectable. Northern blot analysis revealed a sixfold and a fourfold increase in uPA and uPAR mRNA levels in pancreatic cancer, respectively, in comparison with normal controls (P <0.01). Correlation of the Northern blot data with the clinical parameters of the patients indicated that patients with concomitant overexpression of uPA and uPAR had a shorter post-operative survival (median 9 months; mean ± s.d. 10.2 ± 3.6 months) than patients in whom only one or none of these factors were overexpressed (median 18 months; mean ± s.d, 20.3 ± 8.7 months) (P <0.002). Our data suggest that uPA and uPAR may serve as prognostic markers in human pancreatic cancer and that the marked overexpression of both factors may create an environment that enables pancreatic cancer cells to invade surrounding tissues.

KW - Immunohistochemistry

KW - Northern blot analysis

KW - Pancreatic cancer

KW - Urokinase plasminogen activator (uPA)

KW - Urokinase plasminogen activator receptor (uPAR)

UR - http://www.scopus.com/inward/record.url?scp=0031015122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031015122&partnerID=8YFLogxK

M3 - Article

VL - 75

SP - 388

EP - 395

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 3

ER -